ZDEBLOVA CERMAKOVA, Zuzana, Pavel HURNÍK, David KONVALINKA, Jan STEMBIREK, Tereza PARACKOVA, Kamila RESOVA, Jakub CVEK, Tomas BLAZEK, Lukas KNYBEL, Martin FORMANEK, Mariam GACHECHILADZE, Markus JOERGER, Alex SOLTERMANN, Jozef SKARDA, Oldrich MOTYKA a Jana JANOUTOVA. HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy. Medicina-Lithuania. Basel: MDPI, 2023, roč. 59, č. 2, s. 1-12. ISSN 1010-660X. Dostupné z: https://dx.doi.org/10.3390/medicina59020361.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy
Autoři ZDEBLOVA CERMAKOVA, Zuzana (203 Česká republika), Pavel HURNÍK (203 Česká republika, garant, domácí), David KONVALINKA (203 Česká republika), Jan STEMBIREK (203 Česká republika), Tereza PARACKOVA, Kamila RESOVA (203 Česká republika), Jakub CVEK (203 Česká republika), Tomas BLAZEK (203 Česká republika), Lukas KNYBEL (203 Česká republika), Martin FORMANEK (203 Česká republika), Mariam GACHECHILADZE, Markus JOERGER, Alex SOLTERMANN, Jozef SKARDA, Oldrich MOTYKA (203 Česká republika) a Jana JANOUTOVA (203 Česká republika).
Vydání Medicina-Lithuania, Basel, MDPI, 2023, 1010-660X.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30204 Oncology
Stát vydavatele Švýcarsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 2.600 v roce 2022
Kód RIV RIV/00216224:14110/23:00130670
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.3390/medicina59020361
UT WoS 000939961000001
Klíčová slova anglicky oropharyngeal cancer; oral cavity cancer; HPV; RAD51; radiotherapy
Štítky 14110517, rivok
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 8. 3. 2024 12:21.
Anotace
Introduction: The incidence of advanced oral cavity and oropharyngeal cancers is generally high. Treatment outcomes for patients, especially those unfit for comprehensive cancer treatment, are unsatisfactory. Therefore, the search for factors to predict response to treatment and increase overall survival is underway. Objective: This study aimed to analyze the presence of 32 HPV genotypes in tumor samples of 34 patients and the effect of HPV status and RAD51 on overall survival. Method: Tumor samples of 34 patients with locally advanced oropharyngeal or oral cavity cancer treated with accelerated radiotherapy in monotherapy were analyzed using reverse hybridization and immunohistochemistry for the presence of HPV and RAD51. Its effect on overall survival was examined. Results: Only two types of HPV were identified-HPV 16 (dominant) and HPV 66 (two samples). The HPV positivity was associated with a borderline insignificant improvement in 2-year (p = 0.083), 5-year (p = 0.159), and overall survival (p = 0.083). Similarly, the RAD51 overexpression was associated with borderline insignificant improvement in 2-year (p = 0.083) and 5-year (p = 0.159) survival. Conclusion: We found no statistically significant differences but detected trends toward improvement in the survival of HPV-positive and RAD51 overexpressing patients unfit for surgical treatment or chemotherapy treated with hyperfractionated radiotherapy. The trends, however, indicate that in a larger group of patients, the effects of these two parameters would likely be statistically significant.
VytisknoutZobrazeno: 28. 7. 2024 13:13